LIVN Stock Analysis: LivaNova | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 4.199m USD | 12M Return: 49.2% | GB00BYMT0J19 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 48.4M
EPS Trend: 95.5%
Qual. Beats: 2
Rev. Trend: 99.6%
Qual. Beats: 16
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LivaNova PLC (LIVN) is a UK-headquartered medical technology company incorporated in 2015 and listed on NASDAQ. It operates two business segments: Cardiopulmonary, which supplies heart-lung machines, oxygenators, autotransfusion systems, and related disposable perfusion products used in cardiac surgery, and Neuromodulation, which markets the VNS (vagus nerve stimulation) Therapy System for drug-resistant epilepsy and treatment-resistant depression, plus development-stage work on the aura6000 system for obstructive sleep apnea. The company sells primarily to hospitals, surgeons, perfusionists, and neurologists through direct sales representatives, agents, and independent distributors across the United States, major European markets, and other international geographies.
The medical device industry is characterized by long product lifecycles, high regulatory barriers (including FDA and CE Mark approvals), and recurring revenue from disposable and implantable consumables such as oxygenators, perfusion tubing, and replacement pulse generators-elements that underpin LivaNovas mixed capital-and-consumable business model across both of its segments.
- VNS Therapy revenue growth accelerates in Neuromodulation segment
- Cardiopulmonary segment pricing pressured by heart-lung machine competition
- aura6000 sleep apnea system pipeline progress and FDA approval timeline
| Net Income: 188.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.85 > 1.0 |
| NWC/Revenue: 21.61% < 20% (prev 18.26%; Δ 3.36% < -1%) |
| CFO/TA 0.09 > 3% & CFO 249.3m > Net Income 188.6m |
| Net Debt (-106.2m) to EBITDA (134.0m): -0.79 < 3 |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.3m) vs 12m ago 2.91% < -2% |
| Gross Margin: 68.18% > 18% (prev 69.07%; Δ -0.90% > 0.5%) |
| Asset Turnover: 57.17% > 50% (prev 52.23%; Δ 4.94% > 0%) |
| Interest Coverage Ratio: 2.64 > 6 (EBIT TTM 121.7m / Interest Expense TTM 46.1m) |
| A: 0.12 (Total Current Assets 1.03b - Total Current Liabilities 707.0m) / Total Assets 2.64b |
| B: -0.38 (Retained Earnings -1.01b / Total Assets 2.64b) |
| C: 0.05 (EBIT TTM 121.7m / Avg Total Assets 2.57b) |
| D: 1.01 (Book Value of Equity 1.33b / Total Liabilities 1.32b) |
| Altman-Z'' = 0.91 = BB |
| DSRI: 0.96 (Receivables 274.2m/253.0m, Revenue 1.47b/1.31b) |
| GMI: 1.01 (GM 69.07% / 68.18%) |
| AQI: 1.02 (AQ_t 0.49 / AQ_t-1 0.48) |
| SGI: 1.12 (Revenue 1.47b / 1.31b) |
| TATA: -0.02 (NI 188.6m - CFO 249.3m) / TA 2.64b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of October 13, 2026, the stock is trading at USD 77.27 with a total of 1,029,593 shares traded. Over the past week, the price has changed by +1.10%, over one month by -4.17%, over three months by -6.88% and over the past year by +49.23%.
Current recommended Stop Loss: 74.70 (which is 3.3% or 1.2 ATR below the current price).
LivaNova has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy LIVN.
- StrongBuy: 6
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 89.1 | 15.3% |
P/E Trailing = 22.6124
P/E Forward = 16.0
P/S = 2.8532
P/B = 3.2337
P/EG = 0.9256
Revenue TTM = 1.47b USD
EBIT TTM = 121.7m USD
EBITDA TTM = 134.0m USD
Long Term Debt = 289.9m USD (from longTermDebt, last quarter)
Short Term Debt = 12.4m USD (from shortTermDebt, last quarter)
Debt = 410.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 58.5m
Net Debt = -106.2m USD (calculated: Debt 410.4m - CCE 516.6m)
Enterprise Value = 4.09b USD (4.20b + Debt 410.4m - CCE 516.6m)
Interest Coverage Ratio = 2.64 (Ebit TTM 121.7m / Interest Expense TTM 46.1m)
EV/FCF = 27.59x (Enterprise Value 4.09b / FCF TTM 148.3m)
FCF Yield = 3.62% (FCF TTM 148.3m / Enterprise Value 4.09b)
FCF Margin = 10.08% (FCF TTM 148.3m / Revenue TTM 1.47b)
Net Margin = 12.82% (Net Income TTM 188.6m / Revenue TTM 1.47b)
Gross Margin = 68.18% ((Revenue TTM 1.47b - Cost of Revenue TTM 468.3m) / Revenue TTM)
Gross Margin QoQ = 70.07% (prev 67.59%)
Tobins Q-Ratio = 1.55 (Enterprise Value 4.09b / Total Assets 2.64b)
Interest Expense / Debt = 11.24% (Interest Expense 46.1m / Debt 410.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 96.1m (EBIT 121.7m * (1 - 21.00%))
Current Ratio = 1.45 (Total Current Assets 1.03b / Total Current Liabilities 707.0m)
Debt / Equity = 0.31 (Debt 410.4m / totalStockholderEquity, last quarter 1.33b)
Debt / EBITDA = -0.79 (Net Debt -106.2m / EBITDA 134.0m)
Debt / FCF = -0.72 (Net Debt -106.2m / FCF TTM 148.3m)
Total Stockholder Equity = 1.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.33% (Net Income 188.6m / Total Assets 2.64b)
RoE = 15.41% (Net Income TTM 188.6m / Total Stockholder Equity 1.22b)
RoCE = 8.04% (EBIT 121.7m / Capital Employed (Equity 1.22b + L.T.Debt 289.9m))
RoIC = 5.13% (NOPAT 96.1m / Invested Capital 1.87b)
WACC = 8.87% (E(4.20b)/V(4.61b) * Re(8.87%) + D(410.4m)/V(4.61b) * Rd(11.24%) * (1-Tc(0.21)))
Discount Rate = 8.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.85 | Cagr: 1.87%
[DCF] Terminal Value 72.33% ; FCFF base≈153.8m ; Y1≈143.5m ; Y5≈131.1m
[DCF] Fair Price = 36.64 (EV 1.91b - Net Debt -106.2m = Equity 2.01b / Shares 54.9m; r=8.87% [WACC]; 5y FCF grow -8.49% → 2.50% )
EPS Correlation: 95.48 | EPS CAGR: 12.94% | SUE: 0.89 | # QB: 2
Revenue Correlation: 99.55 | Revenue CAGR: 9.98% | SUE: 2.50 | # QB: 16
EPS current Quarter (2026-09-30): EPS=1.06 | Chg30d=+0.22% | Revisions=-42% | Analysts=9
EPS current Year (2026-12-31): EPS=4.36 | Chg30d=+0.31% | Revisions=+75% | GrowthEPS=+11.7% | GrowthRev=+9.7%
EPS next Year (2027-12-31): EPS=4.68 | Chg30d=-0.12% | Revisions=+55% | GrowthEPS=+7.4% | GrowthRev=+7.1%
[Analyst] Revisions Ratio: +34% (up=18, down=8)